Get started
Work

Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.

Year: 2022
Type: conference-abstract
DOI: 10.1200/jco.2022.40.16_suppl.4516
Authors: Jonathan E. Rosenberg, Thomas Powles, Guru P. Sonpavde, Yohann Loriot, Ignacio Duran, Jae-Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel E. Castellano, Ronac Mamtani, Chunzhang Wu, Maria Matsangou, Mary S. Campbell, Daniel P. Petrylak
Institutions: Memorial Sloan Kettering Cancer Center, St Bartholomew's Hospital, Barts Health NHS Trust, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Université Paris-Saclay, Institut Gustave Roussy, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Asan Medical Center, University of Ulsan, National Cancer Center Hospital East, University of Antwerp, Hospital Universitario 12 De Octubre, Abramson Cancer Center, University of Pennsylvania, Astellas Pharma (United States), Seagen (United States), Yale Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: closed
OpenAlex ID: W4286295498
Cites:
Cited by: 22
Related to: 10